跳转至内容
Merck
CN

SML2651

Sigma-Aldrich

Elesclomol

≥98% (HPLC), anticancer agent, powder

别名:

1,3-bis[2-Methyl-2-(phenylthioxomethyl)hydrazide]propanedioic acid, GSK842879A, N′1,N′3-Dimethyl-N′1,N′3-di(phenylcarbonothioyl)malonohydrazide, NSC 174939, NSC174939, STA 4783, STA-4783, STA4783

登录查看公司和协议定价

关于此项目

经验公式(希尔记法):
C19H20N4O2S2
CAS Number:
分子量:
400.52
MDL编号:
UNSPSC代码:
12352200
NACRES:
NA.77
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

Product Name

Elesclomol, ≥98% (HPLC)

方案

≥98% (HPLC)

表单

powder

颜色

white to beige

溶解性

DMSO: 2 mg/mL, clear

储存温度

−20°C

SMILES字符串

S=C(N(NC(=O)CC(=O)NN(C)C(=S)c2ccccc2)C)c1ccccc1

InChI

1S/C19H20N4O2S2/c1-22(18(26)14-9-5-3-6-10-14)20-16(24)13-17(25)21-23(2)19(27)15-11-7-4-8-12-15/h3-12H,13H2,1-2H3,(H,20,24)(H,21,25)

InChI key

BKJIXTWSNXCKJH-UHFFFAOYSA-N

生化/生理作用

Copper (II)-chelating malonohydrazide derivative with in vitro and in vivo anticancer efficacy via reactive oxygen species (ROS) & apoptosis induction.
Elesclomol (STA-4783) is a copper (II)-chelating malonohydrazide derivative that exerts its in vitro and in vivo anticancer efficacy via reactive oxygen species (ROS)/oxidative stress & apoptosis induction in a Cu(II)-dependent manner (GI50 = 12 nM without vs. 129 nM with Cu2+ removal by TRIEN in K562 culture; typical conc. range 0.1-2 μM in cultures). Elesclomol chelates extracellular Cu(II) for mitochondria delivery, where upon Cu2+ reduction (to Cu+) & ROS generation, copper-free elesclomol then exits cells for continual Cu(II) shuttling and accumulation in mitochondria. In addition to Cu2+, elesclomol can also chelate Co2+ and Ni2+, but not Fe3+ or Zn2+.

储存分类代码

11 - Combustible Solids

WGK

WGK 3

闪点(°F)

Not applicable

闪点(°C)

Not applicable


历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本?

如果您需要特殊版本,可通过批号或批次号查找具体证书。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Masazumi Nagai et al.
Free radical biology & medicine, 52(10), 2142-2150 (2012-05-01)
Elesclomol is an investigational drug that exerts potent anticancer activity through the elevation of reactive oxygen species (ROS) levels and is currently under clinical evaluation as a novel anticancer therapeutic. Here we report the first description of selective mitochondrial ROS
Yi-Jie Ren et al.
Frontiers in pharmacology, 8, 804-804 (2017-11-23)
In order to survive under conditions of low oxygen, cancer cells can undergo a metabolic switch to glycolysis and suppress mitochondrial respiration in order to reduce oxygen consumption and prevent excessive amounts of reactive oxygen species (ROS) production. Nucleus accumbens-1
Jia Yu Wang et al.
Cancer research, 77(22), 6226-6239 (2017-09-28)
MTH1 helps prevent misincorporation of ROS-damaged dNTPs into genomic DNA; however, there is little understanding of how MTH1 itself is regulated. Here, we report that MTH1 is regulated by polyubiquitination mediated by the E3 ligase Skp2. In melanoma cells, MTH1
Changyu Zhang et al.
Chemical communications (Cambridge, England), 54(31), 3835-3838 (2018-03-27)
A new fluorescence probe was developed for HClO detection under physiological conditions, which displayed fast response (t1/2 < 30 s) and large off-on fluorescence increase (>1000-fold) toward HClO with high sensitivity and selectivity. The probe was successfully applied for the
W Lu et al.
Oncogene, 36(33), 4719-4731 (2017-04-11)
TP53 plays essential roles in tumor initiation and progression, and is frequently mutated in cancer. However, pharmacological stabilization and reactivation of p53 have not been actively explored for targeted cancer therapies. Herein, we identify a novel Cyclophilin A (CypA) small

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持